Join The Discussion

 

Two from Fort Worth appointed by Gov. Abbott to university boards

Steve Hicks, a University of Texas System regent who has been a vocal opponent of regents who have criticized the system’s flagship campus in Austin, was reappointed to the board by Gov. Greg Abbott on Thursday. 

read more >

Fort Worth draws closer to deal with Lancaster developer

City staff are planning to introduce the developer Feb. 3 at a meeting of the City Council's Housing and Economic Development Committee.

read more >

Compass BBVA names Happel CEO for Fort Worth

BBVA Compass has appointed Brian Happel, most recently the Fort Worth city president, its chief executive officer of Fort Worth.

read more >

Fort Worth minority business receives nationwide grant

Cuevas Distribution Inc., a minority- and woman-owned business in Fort Worth, is one of 20 small businesses nationwide to receive a $150,000 grant from Chase as part of the Mission Main Street program.

read more >

Museum District: Area’s evolution creating more interaction, public spaces

Fifteen years ago if someone had shot a cannon from Fort Worth’s world-renowned museum district, nobody would have noticed, joked Lori Eklund, senior deputy director of the Amon Carter Museum of American Art. But that has changed.

read more >

 

Former TECH Fort Worth client raises $107M in IPO

ZS Pharma Inc., a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, raised nearly $107 million on the NASDAQ capital market from its initial public offering on June 18.
ZS Pharma, a Texas Emerging Technology Fund awardee based in Coppell, also granted the underwriters a 30-day option to purchase up to an additional 891,667 shares of common stock at the IPO price, less underwriting discounts and commissions. The offering is expected to close on or about June 23, subject to customary closing conditions.


ZS Pharma received a $2 million TETF award in 2010 for its development of an orally available sorbent product, ZS-9, which was designed to remove excess potassium from the blood and maintain normal potassium levels. This technology could potentially be used to treat hyperkalemia, a condition that can lead to irregular heartbeat and sudden cardiac death. ZS Pharma was a client of TECH Fort Worth.
J.P. Morgan Securities LLC and Credit Suisse Securities (USA) LLC acted as joint book-running managers for the IPO. BMO Capital Markets Corp. is lead manager and William Blair & Co. LLC is co-manager.
ZS Pharma Inc. is traded under the symbol ZSPH.

Betty Dillard
bdillard@bizpress.net


 

< back

Email   email
hide
Catch
How 'bout them Cowboys?